Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data readouts for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - The company is projected to generate revenue of RMB 1.30 billion in 2025, a 24% year-on-year increase, primarily from overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is forecasted to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is expected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - Revenue projections for 2026E are set at USD 85 million, with gross profit expected to be USD 33 million, maintaining a gross margin of 39.3% [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of registration studies for non-small cell lung cancer (NSCLC). Additionally, the confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are highlighted as key developments [6][12].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data releases for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - Revenue for 2025 is projected at RMB 130 million, a 24% year-on-year increase, primarily driven by overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is expected to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is projected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - The report provides updated revenue forecasts for 2026E at USD 85 million, with a gross profit of USD 33 million and a gross margin of 39.3%. The net loss for 2026E is projected at USD 353 million [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of a registrational study for non-small cell lung cancer (NSCLC). Additionally, confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are expected [6][12].

Core Viewpoint - The article highlights the significant progress and potential of Jinfang Pharmaceutical in the RAS-targeted therapy market, showcasing its comprehensive pipeline and recent financial performance [2][3]. Financial Performance - For the fiscal year 2025, Jinfang Pharmaceutical reported a revenue of RMB 1.30 billion, representing a year-on-year growth of 24.4%, primarily driven by collaboration and licensing agreements with Verastem regarding GFH375 [2]. - The adjusted net loss (non-IFRS) was RMB 227 million, narrowing by 9.3% compared to the previous year, indicating improved operational efficiency [2]. - As of December 31, 2025, the company had cash reserves of RMB 2.074 billion, providing substantial support for the advancement of its pipeline [2]. Product Pipeline and Clinical Development - Jinfang Pharmaceutical has established one of the most comprehensive RAS-targeted therapy matrices globally, including commercial products like Fluorouracil and clinical-stage candidates such as GFH375 and GFH276 [3]. - The first marketed product, Fluorouracil (GFH925, brand name: Daberu®), received approval in August 2024 and was included in the national medical insurance drug list in 2025 [3]. - GFH375 entered Phase III registration clinical trials in November 2025 for the treatment of metastatic pancreatic cancer, marking it as the first KRAS G12D inhibitor undergoing single-agent registration studies globally [3]. - Clinical data for GFH375 showed an overall response rate (ORR) of 40.7% and a disease control rate (DCR) of 96.7% in pancreatic cancer patients, and an ORR of 57.7% and DCR of 88.5% in non-small cell lung cancer (NSCLC) patients, indicating its potential for best-in-class efficacy [3]. Collaborations and Future Prospects - Verastem has initiated multiple single-agent and combination therapy trials for GFH375/VS-7375, with VS-7375 receiving FDA fast track designation for treating KRAS G12D mutant metastatic pancreatic cancer [4]. - The management indicated that Verastem is optimizing dosing for Western populations to support future registration pathways, with a focus on the first-line combination therapy for GFH375, which is gaining attention overseas [5]. - GFH276's clinical trial application was approved in September 2025, with the first patient enrolled, and initial data showing no severe treatment-related adverse events, validating the pharmacokinetic and tissue distribution advantages of its differentiated molecular structure [5][6].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） 自願公告 GFH375獲得國內首個KRAS G12D抑制劑治療 非小細胞肺癌的突破性療法認定 本公告由勁方醫藥科技（上海）股份有限公司（「本公司」或「勁方」，連同其附屬公 司統稱「本集團」）自願刊發，以知會本公司股東及潛在投資者有關本集團最新業 務動態。 關於GFH375/VS-7375 GFH375為口服高活性、高選擇性小分子KRAS G12D(ON/OFF)抑制劑，通過非共 價形式結合KRAS G12D蛋白，抑制其與下游效應蛋白結合，從而在細胞中破壞 KRAS G12D對下游通路的持續活化，最終高效抑制腫瘤細胞增殖。臨床前研究 已顯示GFH375單藥對腫瘤生長的抑制效應隨用藥劑量和週期增長而提升，且在 激酶選擇性和安全性靶點測試 ...

Core Viewpoint - The report by CMB International initiates coverage of Jinfang Pharmaceutical-B (02595) with a "Buy" rating and a target price of HKD 51, highlighting the company's strong management team and innovative drug pipeline focused on challenging RAS targets [1] Group 1: Product Pipeline and Innovation - The company has developed a diversified product pipeline centered around the difficult-to-drug RAS family members, leveraging deep understanding and successful R&D experience to create a candidate matrix that includes KRASG12C/G12D and pan-RAS, among others [2] - The product pipeline extends beyond RAS targets to include other significant indications such as tumors, cachexia, autoimmune, and inflammatory diseases, targeting market opportunities with favorable competitive landscapes [2] Group 2: Clinical Data and Competitive Advantage - The competitive advantage in RAS-targeted drug development is evident in the clinical data for GFH925 and GFH375, with GFH925 showing superior efficacy in 2L+ KRASG12C mutation NSCLC compared to overseas competitors and comparable or better results against domestic rivals [3] - GFH375 is among the first globally to enter Phase III clinical trials for KRASG12D, with promising preliminary data in third-line pancreatic cancer [3] - The dual antibody GDF15/IL-16 (GFS202A) shows early advantages in tolerability and activity compared to single-target drugs [3] Group 3: Management and Strategic Partnerships - The company has assembled a core management team with an average of over 20 years of industry experience, achieving a record of six years from project initiation to market launch for GFH925 [4] - The company actively seeks diverse global development opportunities and strategically selects partners to create value through complementary strengths, collaborating with notable firms such as Innovent Biologics, Merck, and Verastem [4] Group 4: Financial Projections and Valuation - The company is projected to achieve revenues of RMB 1.09 billion, 0.85 billion, and 1.18 billion in 2025-2027, primarily driven by sales of GFH925 in China and overseas collaboration for GFH375 [5] - Based on a DCF valuation model, the target price of HKD 51 corresponds to a 2.3x revenue peak sales multiple and an 87% potential upside [5] - Future focus includes monitoring the sales ramp-up of GFH925 post-reimbursement inclusion and additional data readouts from the RAS pipeline [5]

Core Viewpoint - The report by CMB International initiates coverage of Jinfang Pharmaceutical-B (02595) with a "Buy" rating and a target price of HKD 51, highlighting the company's innovative drug pipeline and strong management team [1] Group 1: Product Pipeline and Innovation - The company has established a diversified product pipeline focused on challenging RAS targets, leveraging deep understanding and successful development experience to create a candidate matrix that includes KRASG12C/G12D and pan-RAS, among others [1] - GFH925 (Fuzeracib) has been approved for marketing in mainland China, marking it as the first domestic product targeting the same RAS family member [1] - The product pipeline also extends to other significant indications such as tumors, cachexia, autoimmune, and inflammatory diseases, targeting promising areas like RIPK1 and GDF15/IL-6 [1] Group 2: Clinical Data and Competitive Advantage - The company demonstrates a competitive edge in RAS-targeted drug development, with GFH925 showing excellent efficacy in 2L+ KRASG12C mutation non-small cell lung cancer (NSCLC) patients, outperforming overseas competitors [2] - GFH375 is among the first globally to enter Phase III clinical trials for KRASG12D, showing promising initial data compared to major competitors [2] - The dual antibody GFS202A targeting GDF15/IL-16 is progressing rapidly, with early signs of tolerability and activity advantages over single-target drugs [2] Group 3: Management and Strategic Partnerships - The company has assembled a core management team with an average of over 20 years of industry experience, achieving a record of six years from project initiation to market launch for GFH925 [3] - The company actively seeks diverse global development opportunities and strategically selects partners to create value through complementary strengths, collaborating with notable firms such as Innovent Biologics, Merck, and Verastem [3] Group 4: Financial Projections and Valuation - The company is projected to achieve revenues of RMB 1.09 billion, 0.85 billion, and 1.18 billion in 2025-2027, primarily driven by sales of GFH925 in mainland China and overseas collaboration income from GFH375 [4] - Using a DCF valuation model, the target price of HKD 51 corresponds to a 2.3x peak revenue sales multiple and an 87% potential upside [4] - Future focus will be on the sales ramp-up of GFH925 post-inclusion in medical insurance and additional data readouts from the RAS pipeline [4]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Viewpoint - The announcement highlights the initiation of a pivotal Phase III trial (GFH375X1301) for the oral KRAS G12D inhibitor GFH375, targeting previously treated patients with metastatic pancreatic cancer, marking a significant advancement in the treatment landscape for this aggressive disease [1][2]. Group 1: Clinical Development - GFH375 is currently in the leading tier of global oral KRAS G12D inhibitors, with multiple clinical explorations ongoing both in China and internationally [1]. - The Phase III trial will be conducted at approximately 40 centers, aiming to enroll around 320 patients who have previously received at least one standard systemic treatment for metastatic pancreatic cancer [2]. - GFH375 has received FDA Fast Track designation for the treatment of locally advanced and metastatic KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC) [1]. Group 2: Market Context - Pancreatic cancer is characterized by high malignancy and poor prognosis, with a 5-year survival rate of less than 10%, and the global incidence of new cases is projected to exceed 770,000 by 2037 [2]. - Current treatment options primarily involve chemotherapy, with objective response rates (ORR) for second-line to third-line treatments only ranging from 10% to 20%, and no standard treatment available for third-line and beyond [2]. - Nearly 40% of pancreatic cancer patients exhibit KRAS G12D mutations, which are independent prognostic markers associated with poor response rates and overall survival [2]. Group 3: Company Insights - The Chief Medical Officer of the company emphasized that this is the first global oral RAS inhibitor clinical study for pancreatic cancer, showcasing the company's capabilities in clinical research and integrated drug development [3]. - The company anticipates positive outcomes from the GFH375X1301 trial, which could benefit patients and lead to further breakthroughs in RAS-targeted therapies [3]. - GFH375 is expected to synergize with the company's dual antibody therapy for a comprehensive treatment approach to pancreatic cancer [3].

Core Viewpoint - The company has initiated a pivotal Phase III trial (GFH375X1301) for its oral KRAS G12D inhibitor GFH375, targeting previously treated patients with KRAS G12D mutant metastatic pancreatic cancer, marking a significant advancement in the treatment landscape for this aggressive cancer type [1][2]. Group 1: Clinical Development - The Phase III trial will be conducted at approximately 40 centers, aiming to enroll around 320 patients who have previously received at least one standard systemic treatment for metastatic pancreatic cancer [2]. - GFH375 is currently in the leading tier of global oral KRAS G12D inhibitors, with multiple clinical explorations ongoing both in China and internationally [1][2]. - The drug has received FDA Fast Track designation for the treatment of locally advanced and metastatic KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC) [1]. Group 2: Market Context - Pancreatic cancer is characterized by high malignancy and poor prognosis, with a 5-year survival rate of less than 10%, and the global incidence of new cases is projected to exceed 770,000 by 2037 [2]. - Approximately 40% of pancreatic cancer patients harbor the KRAS G12D mutation, which is an independent prognostic marker associated with poor response rates and overall survival in advanced PDAC [2]. Group 3: Company Insights - The Chief Medical Officer of the company highlighted that this is the first global oral RAS inhibitor clinical study for pancreatic cancer, showcasing the company's capabilities in clinical research and integrated drug development [3]. - The company anticipates positive outcomes from the GFH375X1301 study, which could benefit patients and lead to further breakthroughs in RAS-targeted therapies [3].

Core Insights - The phase of capital frenzy driven by innovative drugs in China is coming to an end, but the long-term value of the Chinese innovative drug industry is becoming clearer, ushering in a more expansive era [1] - The essence of global innovation competition revolves around unmet clinical needs, particularly in high-mortality and low-survival-rate disease areas, where Chinese pharmaceutical companies are developing innovative therapies that are leading in the market [1][2] Group 1: Industry Trends - The narrative of Chinese innovative drugs remains focused on technological breakthroughs and research efficiency, positioning them as disruptors in the global arena [2] - Chinese biotech companies are demonstrating global competitiveness in hot areas, such as KRAS G12D, with significant developments showcased at recent conferences [2][3] - The demand for innovative treatments is driven by patients' survival needs, making them the ultimate price setters in the pharmaceutical innovation landscape [2] Group 2: GFH375 Developments - GFH375 has shown a 40.7% objective response rate (ORR) in patients with pancreatic ductal adenocarcinoma (PDAC), significantly higher than current standard chemotherapy treatments [2][3] - The patient population for GFH375 includes a high proportion of late-stage patients, indicating its potential effectiveness in difficult-to-treat cases [4] - Preliminary data from ongoing trials suggest that GFH375 may become a leading treatment option in the KRAS G12D space, with promising results in both Chinese and U.S. studies [7][8] Group 3: Market Potential - The global incidence of pancreatic cancer is projected to rise, with an estimated 542,000 new cases in 2024, highlighting the urgent need for effective treatments [10] - The market dynamics favor companies that can address large patient populations with unmet clinical needs, positioning GFH375 as a potential standard of care in its field [10][11] - The competitive landscape includes other innovative therapies, but GFH375's safety profile and efficacy suggest it may outperform existing options [13][14] Group 4: Broader Implications - The RAS mutation covers approximately 30% of cancer patients, indicating a significant market opportunity for therapies targeting this pathway [20] - Companies like Jinfang Pharmaceutical are not only focusing on single molecules but are also developing comprehensive treatment matrices, enhancing their competitive edge [20] - The industry is expected to shift towards a more rational phase, focusing on companies with solid fundamentals, which may lead to a more sustainable growth trajectory [21]